Agilent Technologies reports this evening with the Street's patience for a delayed recovery finally being tested by a live print.
The options market is sending a notably neutral signal into the release. The put/call ratio of 0.74 is almost exactly in line with its 20-day average of 0.73 — a z-score near zero — suggesting options traders have not moved to position defensively or aggressively ahead of the number. That is a change from earlier in May, when the PCR ran as high as 0.90 before drifting back. Borrow conditions reinforce the lack of conviction on the short side: availability is essentially unconstrained, with more than 280 million shares available to lend, and the cost to borrow is a negligible 0.42%. Short interest is only 1.7% of the free float and has drifted lower over the past week. There is no meaningful short pressure in the setup.
The real tension is in the analyst picture — and it has shifted slightly since the last preview. Baird raised its target modestly to $156 yesterday, maintaining its Outperform. That nudge higher is the first upward target revision in months, following a long sequence of cuts from Barclays, TD Cowen, Evercore, Morgan Stanley, UBS, and Wells Fargo that pushed the consensus mean down to roughly $161 from peaks above $180. Every firm that trimmed kept a positive rating intact, and the stock now trades at $115.08 — more than 39% below that consensus mean. The EPS forward growth score ranks in the 91st percentile of the universe, a sign the Street still expects recovery; but the EPS surprise factor, ranked only in the 34th percentile, reflects a recent history of missing or only modestly beating estimates.
Peer performance this week adds another layer to the read. RGEN and BRKR both posted strong weekly gains — up 10.5% and 9.8% respectively — while WAT lagged at under 2%. Agilent's own 4.1% rise over the week broadly tracks the group's recovery, but it has not broken out from it. The three most recent earnings prints all produced negative one-day reactions, with moves ranging from -0.9% to -2.8%. The five-day window was worse: two of those three events saw the stock still lower five days later, by as much as 4.9%.
The print is therefore less about whether Agilent's recovery thesis is intact and more about whether the company can demonstrate enough concrete progress — in China end markets and biopharma capital spending — to justify why the 39% gap to consensus targets should start to close rather than widen further.
See the live data behind this article on ORTEX.
Open A on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
